A recent study, published in the New England Journal of Medicine has found that a new drug, lecanemab may slow down the cognitive deterioration in Alzheimer's patients, which could offer novel treatments for the neurodegenerative illness. The study concluded that lecanemab would be a positive step in treating patients with Alzheimer’s.
About the Study
Since Alzheimer's is a complex disease with numerous underlying causes connected to the biology of ageing, the Alzheimer's Drug Discovery Foundation (ADDF) has long maintained that a combination drug approach is necessary, stated the study. The findings of this recent study were presented at the 15th edition of the Clinical Trials on Alzheimer's Disease Conference (CTAD).
Amyloid-clearing drugs are one component of the solution. But there is a need to develop a new generation of drugs targeting all facets of the biology of ageing, in order to address the full spectrum of underlying pathologies contributing to the disease, according to the study.
Amyloid beta, a kind of protein that is found in the brain, is the first factor in Alzheimer's disease. This protein begins to accumulate into plaques more than two decades before people experience their first neurological issues. Tau tangles, a brain protein start forming after the amyloid buildup. In this, cognitive deterioration follows after tissues in the affected areas start to wither and die.
The study stated that new and easy-to-use diagnostic techniques can aid in identifying the exact causes of Alzheimer's in people. This would enhance clinical trials and enable precision in treatment.
The study results are encouraging and give a clear picture of when treatments will enable patients to maintain their independence for years longer—possibly for the rest of their lives—rather than just for a few more weeks or months.